Ibex Medical Analytics Announces Expansion of its Biopharma Business, Extending AI Pathology Platform into Early Biomarker Development
Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of its biopharma business. Building on its successful collaborations in late-stage biomarker development, Ibex is now extending its platform into earlier translational research, biomarker development, and trial-efficiency optimization.
Ibex’s high-performance AI platform—already deployed across more than 50 health systems worldwide and used in collaboration with major industry organizations such as Philips and Roche—now supports exploratory, preclinical, and clinical evidence generation, while providing a seamless foundation for future companion diagnostic (CDx) programs.